|
|
|
|
Selecting a CDMO isn't just entering a transactional relationship. You are forming a long-term partnership that can impact the success of your current product and benefit the manufacturing of future products. Review some of the "intangible" decision factors, how they can shape your CDMO search, and what types of questions you can ask to assess them.
|
|
|
|
|
Biotech companies face external pressure to rush their cell and gene therapies into trials. But a significant amount of work must be done prior to clinical manufacturing, such as defining the product profile and corresponding specifications. Learn more as this panel explores the pitfalls for developers and the key indicators of GMP readiness.
|
|
|
|
|
It can be difficult to objectively assess your GMP-readiness and know when it is time to move forward to clinical manufacturing. Ensuring that your product can be consistently produced by manufacturing operators is not a trivial matter. Find out how to assess scalability, repeatability, and overall GMP-readiness of your process and documentation.
|
|
|
|
|
Cell therapies hold the potential to revolutionize treatment possibilities, but their tailored approach often leads to higher costs, slower timelines, and limited scalability. Learn how the streamlined processes and reduced complexity enabled by a platform approach can lead to scalable manufacturing, rapid delivery, and expanded patient access.
|
|
|
|
OUTSOURCED PHARMA CAPACITY UPDATE
|
|
|
|
|
|
|
|
|
|
|
|
|
